FOURIER Cost, Cost-Effectiveness, and Health-Economic Implications

By
Published Updated Last reviewed
Prescription access and medication affordability image for FOURIER Cost, Cost-Effectiveness, and Health-Economic Implications

FOURIER Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

| Field | Detail | |---|---| | Trial | FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) | | N | 27,564 | | Intervention | Evolocumab 140 mg SC Q2W or 420 mg SC monthly + statin | | Comparator | Placebo + statin | | Duration | Median 2.2 years | | Primary Endpoint | Composite MACE: CV death, MI, stroke, hospitalization for UA, or coronary revascularization | | Key Result | 15% relative risk reduction in primary endpoint (HR 0.85 to 95% CI 0.79, 0.92, p <0.001); 20% RRR in key secondary endpoint (CV death, MI, stroke) | | Economic Angle | Cost-per-QALY at list price ~$450,000, $750,000; at modeled net price ~$100,000, $150,000 depending on risk stratum |

Why the Economics Matter as Much as the Efficacy

The efficacy signal from FOURIER was clear enough. Adding evolocumab to background statin therapy in patients with established atherosclerotic cardiovascular disease (ASCVD) cut the composite MACE rate from 11.3% to 9.8% over a median 2.2 years. That 1.5 percentage-point absolute risk reduction sounds modest at first glance, but it was generated in a highly-treated population already on intensive statin therapy with a median LDL-C of 92 mg/dL at baseline.

The harder question was never whether the drug worked. It was whether society could afford to give it to the roughly 8 million U.S. patients who qualified based on the trial's enrollment criteria. At launch in 2015, the annual list price for evolocumab (Repatha) sat near $14,500 per year. When you multiply that by even a fraction of eligible patients, the fiscal pressure on payers becomes enormous. That tension is why health-economic modeling of FOURIER became its own sub-literature, with at least a dozen independent cost-effectiveness analyses published between 2017 and 2023.

How the Models Were Built

The ICER Framework

The Institute for Clinical and Economic Review (ICER) published the most widely cited independent U.S. cost-effectiveness analysis of PCSK9 inhibitors in 2015 (updated after FOURIER in 2017). ICER used a Markov state-transition model with health states anchored to the event categories in FOURIER: fatal and non-fatal MI, fatal and non-fatal stroke, coronary revascularization, and all-cause death. Each state carried published utilities drawn from EQ-5D data in prior cardiovascular trials. The model's time horizon was lifetime, projecting FOURIER's 2.2-year trial results forward using exponential extrapolation of event hazard rates.

Three input choices drove most of the variance across models:

  1. Drug acquisition cost. List price, estimated net price after rebates, or a target "value-based price" back-calculated from a $100,000/QALY threshold.
  2. Time horizon and treatment duration. Short models (matching trial follow-up) produced far worse ICER estimates than lifetime models, because most of the QALY gain from preventing a non-fatal MI accrues over the remaining life-years of a 60-year-old.
  3. Baseline event rate. Patients with higher baseline MACE risk generate more preventable events per patient-year of treatment, dramatically improving the cost-effectiveness ratio.

The ICER 2017 update estimated cost-per-QALY at list price between $450,000 and $750,000 depending on model assumptions. That range was consistently above the $100,000, $150,000 threshold that U.S. payers and most academic health economists use as a reference standard.

The Kazi et al. Model

A frequently cited independent analysis by Kazi and colleagues (published in JAMA Cardiology, 2017) used patient-level event data from FOURIER to calibrate a microsimulation. Their central finding: at a list price of $14,350/year, evolocumab cost $450,000 per QALY gained. To reach a $100,000/QALY threshold, the annual price would need to fall to approximately $3,200. At $150,000/QALY, the threshold price was approximately $4,500. These figures proved influential in subsequent payer negotiations and in the FDA's approval language context discussions.

The Kazi model also stratified by baseline MACE risk. In the highest-risk quartile (patients with multiple prior MIs and additional high-risk features), the cost-per-QALY at list price fell to roughly $300,000. Still above threshold, but materially better than the overall population estimate.

European Models

Several European analyses used local healthcare costs and reported cost-per-QALY figures in euros or pounds, with different conclusions because drug pricing differs substantially. A UK NICE appraisal (2016, updated 2021) concluded that evolocumab was cost-effective at the confidential commercial price (not publicly disclosed) for patients with established ASCVD and LDL-C persistently above 2.6 mmol/L on maximally tolerated statin therapy. NICE approved coverage under those conditions. The gap between U.S. and European health-economic conclusions for the same clinical data illustrates how acquisition price, not clinical evidence, is the dominant variable.

List Price vs. Net Price: What Actually Matters

The list price of evolocumab remained near $14,000 annually through 2018. Amgen then reduced the list price to approximately $5,850 per year in October 2018, following sustained payer pressure and market competition from alirocumab (Praluent). Net prices after rebates were lower still and are not publicly disclosed, but analysts estimated real payer cost in the $3,500, $5,000 range by 2019 for many large payers.

This price shift is not a minor footnote. At $5,850 list and assuming a net price around $4,500, the Kazi model framework implies cost-per-QALY falling close to the $100,000, $150,000 range for the overall FOURIER population, and below $100,000 for high-risk subgroups. The cost-effectiveness picture changed substantially without any new clinical data being generated. This is a structural feature of pharmacoeconomics that the clinical literature often understates: the same RCT can go from "not cost-effective" to "cost-effective" within three years, driven entirely by commercial negotiation.

Which Patients Clear the Value Threshold?

The FOURIER trial enrolled patients with established ASCVD and LDL-C ≥70 mg/dL on statin therapy. Within that population, there are meaningful differences in absolute risk and therefore in cost-effectiveness. FOURIER pre-specified a high-risk subgroup analysis that identified patients with multiple prior MIs, prior MI plus peripheral artery disease, or prior MI plus prior stroke as having higher absolute event rates and larger absolute risk reductions.

At current net pricing (estimated $4,500, $5,500/year), health-economic models suggest cost-per-QALY is most favorable, likely below $100,000, for patients with:

| Risk Feature | Approximate Baseline 2-Year MACE Rate | Cost-Per-QALY at ~$5,000/yr Net | |---|---|---| | Multiple prior MIs | ~14 to 16% | <$100,000 | | Prior MI + PAD | ~13 to 15% | ~$80,000, $110,000 | | Prior MI + stroke | ~12 to 14% | ~$90,000, $120,000 | | Single prior MI, no other high-risk features | ~8 to 10% | ~$150,000, $220,000 | | LDL-C ≥100 mg/dL on statin, no high-risk features | ~7 to 9% | ~$180,000, $280,000 |

Estimates are model-derived approximations; actual figures vary by model assumptions and year-of-analysis pricing.

The table has a direct clinical implication. Prescribers and patients deciding whether to pursue authorization for evolocumab should anchor the conversation to absolute risk, not just the relative 15% MACE reduction. A patient with a 15% two-year MACE risk gets approximately twice the absolute benefit from the same relative risk reduction compared to a patient with a 7.5% baseline risk, at the same drug cost.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction acknowledges this explicitly, recommending PCSK9 inhibitors preferentially in very high-risk ASCVD patients when LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe.

Payer Coverage: The Prior Authorization Gauntlet

Even where cost-effectiveness models show acceptable ratios, real-world access has been an obstacle. Following FOURIER publication in 2017, commercial payer approval rates for PCSK9 inhibitors were reported as low as 25 to 50% in some analyses. The typical prior authorization criteria impose several layers: documentation of maximally tolerated statin therapy, prior trial of ezetimibe, LDL-C threshold (often ≥70 mg/dL for ASCVD, ≥100 mg/dL for primary prevention), and specific ASCVD diagnosis codes.

These administrative barriers exist because the payer-side cost-effectiveness argument was weakest at list price. As net prices have moved, some plans have reduced prior authorization burden, though this varies considerably by insurer and formulary tier.

Medicare Part D covers evolocumab but places it on specialty tiers with cost-sharing that can reach the beneficiary out-of-pocket cap under the Inflation Reduction Act's 2025 redesign (annual out-of-pocket maximum $2,000). For Medicare patients, the out-of-pocket math changed substantially under the IRA, potentially improving real-world adherence in this high-risk demographic.

Amgen's Repatha patient assistance and co-pay card programs have historically capped commercial-insured patient out-of-pocket at $5/month for eligible patients, though this does not apply to government payers.

Methodological Criticisms of the Economic Analyses

Several limitations in the FOURIER-derived cost-effectiveness literature deserve attention:

Short trial horizon problem. The trial ran a median 2.2 years. Extrapolating to lifetime benefit requires assumptions about whether the hazard reduction persists after treatment stops or is maintained indefinitely on treatment. Most models assume sustained reduction, which is optimistic but defensible given the LDL-lowering mechanism. The FOURIER-OLE open-label extension provided some real-world support for durable benefit, but was not powered for formal statistical confirmation.

No CV mortality signal in the parent trial. Cardiovascular death did not differ significantly between arms in the main FOURIER analysis (HR 1.05 to 95% CI 0.88, 1.25). Models that assign QALY weight heavily to mortality benefit rather than non-fatal event prevention therefore produce worse cost-effectiveness ratios than models weighted toward quality-of-life impacts of non-fatal MI and stroke. This is a genuine scientific uncertainty, not just a modeling choice.

Utility values for non-fatal events vary across studies. The QALY decrement attached to a non-fatal MI in the cardiac surgery literature ranges from about 0.06 to 0.18 depending on source and patient population. This range alone can shift the cost-per-QALY estimate by tens of thousands of dollars.

Discount rate sensitivity. Standard economic models discount future QALYs at 3%/year. Lower discount rates improve the cost-effectiveness of preventive therapies by weighting distant QALY gains more highly. Some analysts have argued that cardiovascular prevention drugs are systematically undervalued by standard discount rates.

Individual Patient Decision Framework

For a clinician and patient working through the value calculation together, the practical questions are:

  1. What is this patient's absolute 10-year ASCVD risk, and more specifically, their expected 2 to 5 year MACE probability given established disease and current LDL-C?
  2. Has maximally tolerated statin therapy plus ezetimibe been tried and documented?
  3. What is the patient's actual out-of-pocket cost after insurance, assistance programs, and Part D redesign?
  4. What is the patient's personal weighting of a non-fatal MI versus a monthly injection and possible injection-site reactions?

The economics shift materially once personal cost falls below $100, 200/month. At $5/month with a co-pay card or $167/month at the Medicare out-of-pocket cap, even moderate-risk ASCVD patients can achieve favorable personal cost-effectiveness ratios. The societal cost-effectiveness question and the individual patient affordability question are related but distinct, and conflating them leads to poorly calibrated shared decision-making.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. https://pubmed.ncbi.nlm.nih.gov/28304224/

  2. Kazi DS, Moran AE, Coxson PG, et al. Cost-Effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016;316(7):743-753. https://pubmed.ncbi.nlm.nih.gov/27533159/

  3. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cardiol. 2018;3(9):823-828. https://pubmed.ncbi.nlm.nih.gov/30073316/

  4. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022;146(15):1109-1119. https://pubmed.ncbi.nlm.nih.gov/35900965/

  5. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. https://pubmed.ncbi.nlm.nih.gov/30423393/

  6. Repatha (evolocumab) Prescribing Information. Amgen. FDA Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf